Merck said worldwide sales in 2024 were $64.2 billion, an increase of 7% compared with 2023, or 10% excluding the unfavorable effect of foreign exchange.

1. 01

   Merck said worldwide sales in 2024 were $64.2 billion, an increase of 7% compared with 2023, or 10% excluding the unfavorable effect of foreign exchange.

2. 02

   The company cited growth in oncology, cardiovascular and animal health as drivers of the 2024 sales increase, partially offset by declines in diabetes, virology (driven largely by lower sales of Lagevrio), immunology and vaccines.

3. 03

   Merck returned $9.1 billion to shareholders in 2024 through dividends of $7.8 billion and share repurchases of $1.3 billion, and said its Board of Directors approved in January 2025 a new share repurchase program of up to an additional $10 billion.

4. 04

   The company launched Winrevair and Capvaxive in the U.S. in 2024, received more than 25 regulatory approvals in major markets and closed exclusive global licenses with LaNova Medicines Ltd and Hansoh Pharma, as well as acquired EyeBiotech Limited and Harpoon Therapeutics, Inc.

Key figures

Fiscal year ended December 31, 2024

Revenue

$64.2B

Net income

$17.1B

EPS

$6.74

Operating cash flow

$21.5B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.